SciELO - Scientific Electronic Library Online

 
vol.61 issue2Introduction and Aims: Combined treatment with pegylated interferon and lamivudine can constitute a suitable alternative in order to obtain seroconversion in pediatric patients with virus B chronic infection. The aim of the present study was to evaluate the response of pediatric patients with chronic virus B infection given by the lost of Age VHB and DNA VHB, and the appearance of antibodies against Age VHB and normalization of aminotranferases in patients treated with pegylated interferon alpha 2a in combination with lamivudine. Patients and Methods: Pediatric patients with chronic infection by virus B were included, with positive HBe Ag, anti- HBe Ab-, HBV DNA positive, elevation of aminotranferases for more than 6 months These patients received treatment with pegylated interferon alpha 2a and lamivudine 4 mgs/kg/day for 52 weeks. Results: The transmission routes were vertical in 2 patients, transfusional in 7and 1 unknown. PatientÊs mean age was 10,3+ 3,47 years, with an average time of exposure to virus B of 5,2+3,93 years. The average of aminotranferases at the beginning of treatment was AST 112,3+46,3 and ALT 127,8 + 44. Twelve weeks following treatment AST levels were 33,3+12,14 and ALT 35,5+ 13,51.The histological findings were: 2 patients had moderate inflammatory activity, 8 mild activity , 2 developed moderate fibrosis and 8 mild fibrosis. Only 1 patient developed anemia and leucopenia that did not require the suspension of treatment. Ten (10) patients (100%) developed fever, 8 (80%) migraine during the 4 first weeks of treatment; they remained asymptomatic during the 48 remaining weeks. The 10 patients had normal aminotranferases at 12 weeks following treatment. Two (2) (20%) of the patients presented loss of Ags VHB and Ac positive Ags VHB 12 weeks post treatment. Of 10 patients 4 (40%) had seroconversion (Age VHB, negative DNA VHB and Ab positive Age VHB) by week 52 of treatment and 12 weeks post treatment. Conclusion: Combined treatment with pegylated interferon and lamivudine constitute an effective and safe therapeutic option for pediatric patients with chronic infection by virus B.Pólipos de estómago y duodeno: Una revisión de 1 año de experiencia en un centro de referencia author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • Have no similar articlesSimilars in SciELO

Share


Gen

Print version ISSN 0016-3503On-line version ISSN 2477-975X

Abstract

ROJAS, Beatriz et al. Manejo endoscópio de las complicaciones biliares post-transplante hepático experiencia en Venezuela. Gen [online]. 2007, vol.61, n.2, pp.108-110. ISSN 0016-3503.

Las complicaciones biliares se presentan en 13 a 35% de los pacientes en quienes se realiza transplante hepático,siendo la CPRE un método endoscópico utilizado para su resolución. Objetivo: mostrar la experiencia en Venezuela del manejo endoscópico de las complicaciones biliares postransplante hepático ortotópico incluyendo estenosis anastomótica, fístula biliar y distorsión anatómica (acodamiento de la vía biliar). Pacientes y métodos: desde el año 2003 se realizaron 16 transplantes hepáticos ortotópicos presentándose complicaciones biliares en 7 de ellos (43,75%). Se realizó la CPRE en su totalidad. Resultados: se encontraron 3 casos de fístula biliar, 1 estenosis supraanastomótica, 1 casos de estenosis anastomótica y 2 casos de acodamiento de la vía biliar. Se realizó esfinterotomía endoscópica más colocación de prótesis biliar en 5 pacientes, esfinterotomía más dilatación con balón y colocación de prótesis en 1 paciente y esfinterotomía sola en 1 paciente. No hubo complicaciones por el procedimiento y los pacientes presentaron evolución satisfactoria. Conclusión: el diagnóstico y la realización precoz de procedimientos terapéuticos endoscópicos como la CPRE, constituyen herramientas fundamentales para la resolución de las complicaciones biliares postransplante hepático.

Keywords : transplante hepático; estenosis; fístula; CPRE.

        · text in Spanish

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License